CN106687107B - 抗产甲烷组合物及其用途 - Google Patents

抗产甲烷组合物及其用途 Download PDF

Info

Publication number
CN106687107B
CN106687107B CN201580050231.6A CN201580050231A CN106687107B CN 106687107 B CN106687107 B CN 106687107B CN 201580050231 A CN201580050231 A CN 201580050231A CN 106687107 B CN106687107 B CN 106687107B
Authority
CN
China
Prior art keywords
weight
formulation
lovastatin
statin
modified release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580050231.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106687107A (zh
Inventor
M·皮门特尔
R·马图尔
S·堪泽尔
V·瓦彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Theriva Biologics Inc
Original Assignee
Cedars Sinai Medical Center
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Synthetic Biologics Inc filed Critical Cedars Sinai Medical Center
Publication of CN106687107A publication Critical patent/CN106687107A/zh
Application granted granted Critical
Publication of CN106687107B publication Critical patent/CN106687107B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580050231.6A 2014-08-13 2015-08-13 抗产甲烷组合物及其用途 Expired - Fee Related CN106687107B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462036948P 2014-08-13 2014-08-13
US62/036,948 2014-08-13
US201462043649P 2014-08-29 2014-08-29
US201462043789P 2014-08-29 2014-08-29
US62/043,649 2014-08-29
US62/043,789 2014-08-29
US201562141355P 2015-04-01 2015-04-01
US62/141,355 2015-04-01
PCT/US2015/045140 WO2016025762A1 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN106687107A CN106687107A (zh) 2017-05-17
CN106687107B true CN106687107B (zh) 2020-12-25

Family

ID=55301332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050231.6A Expired - Fee Related CN106687107B (zh) 2014-08-13 2015-08-13 抗产甲烷组合物及其用途

Country Status (12)

Country Link
US (5) US9956292B2 (enExample)
EP (1) EP3179983A4 (enExample)
JP (1) JP6667526B2 (enExample)
KR (1) KR102425303B1 (enExample)
CN (1) CN106687107B (enExample)
AU (1) AU2015301596B2 (enExample)
BR (1) BR112017002761A2 (enExample)
CA (1) CA2955666A1 (enExample)
IL (1) IL250568B (enExample)
MX (1) MX2017001971A (enExample)
RU (1) RU2697851C2 (enExample)
WO (1) WO2016025762A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US12071673B2 (en) 2013-03-15 2024-08-27 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014239164B2 (en) 2013-03-15 2018-12-06 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
RU2697851C2 (ru) 2014-08-13 2019-08-21 Седарс-Синаи Медикал Сентер Антиметаногенные композиции и их применение
EP4512394A3 (en) 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
US10219518B2 (en) * 2015-09-18 2019-03-05 Environmental Intellectual Property, Inc. Inhibition of methanogenesis to control wood boring insects and pestilence
US20190277833A1 (en) * 2016-05-19 2019-09-12 Synthetic Biologics, Inc. Anti-methanogenic compositions
WO2017223177A1 (en) * 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses
BR112019012062A2 (pt) * 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
TW201834710A (zh) * 2016-12-14 2018-10-01 美商寶珍那提公司 以整合素抑制劑治療胃腸道疾病
WO2018112240A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN110290781A (zh) 2017-01-26 2019-09-27 南京三迭纪医药科技有限公司 胃肠特定部位控制释放的剂型
EP3641732A1 (en) * 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
BR112021004523A2 (pt) * 2018-09-10 2021-06-08 Argenta Innovation Limited formulações para liberação sustentada em dispositivos de administração
BR112022005755A2 (pt) * 2019-10-09 2022-06-21 Scherer Technologies Llc R P Formulações de cápsula de gel macio não animal, métodos de preparação, e métodos de uso das mesmas
PT4037666T (pt) 2020-12-08 2024-06-25 Ruminant Biotech Corp Ltd Aperfeiçoamentos de dispositivos e métodos para administração de substâncias a animais
WO2023069904A1 (en) * 2021-10-19 2023-04-27 Cedars-Sinai Medical Center Daily fasting methane to detect intestinal methanogen overgrowth and monitor treatment response
US20240334952A1 (en) * 2021-12-23 2024-10-10 Fonterra Co-Operative Group Limited Use of lactic acid bacteria to improve feed efficiency
US12084610B2 (en) 2022-07-01 2024-09-10 Arkea Bio Corp. Compositions and methods for reducing deleterious atmospheric gas emissions from flooded ecosystems
WO2025036806A1 (en) * 2023-08-15 2025-02-20 Evonik Operations Gmbh An enteric coated hard shell capsule for delivery of a dosage form in the ileum and colon
US12448600B2 (en) 2023-08-24 2025-10-21 Synergraze Inc. Extraction of antimethanogenic compounds
US12281342B2 (en) 2023-08-24 2025-04-22 Synergraze Inc. Extraction of antimethanogenic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100023A2 (en) * 2002-05-20 2003-12-04 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
WO2006102350A1 (en) * 2005-03-23 2006-09-28 Washington University In St. Louis The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
CN101312716A (zh) * 2005-09-30 2008-11-26 Impax实验室公司 具有速释和/或控释特征的药物剂型
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225202A (en) * 1880-03-02 Clothes-slide
GB423083A (en) 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
DK0724454T3 (da) 1993-10-19 2004-07-12 Commw Scient Ind Res Org Fremgangsmåde til forbedring af drövtyggerdyrs eller drövtyggerlignende dyrs udnyttelse af næringsstoffer
US5447850A (en) 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CN1119154C (zh) 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
US6328959B1 (en) 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
WO2000033821A1 (en) * 1998-12-07 2000-06-15 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
JP2003513036A (ja) 1999-11-03 2003-04-08 ハワード ジェイ．スミス アンド アソシエイツ ピーティーワイ リミテッド 肝臓選択的な治療方法
GB2371748B (en) 1999-11-08 2004-12-01 Andrx Corp HMG-COA reductase inhibitor extended release formulation
CN1330253C (zh) 2000-06-13 2007-08-08 荷兰联合利华有限公司 含有无活力乳酸杆菌的食物制品
US6299774B1 (en) 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
DE60224189T2 (de) * 2001-06-20 2008-12-11 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
BR0312936B8 (pt) 2002-07-18 2021-07-27 Agricultural Research Council aditivo alimentício, método para melhorar desempenho de ruminantes, bem como método de isolamento de uma cultura biologicamente pura de um micro-organismo ruminal superior
EP1545503A4 (en) 2002-09-03 2007-12-12 Circ Pharma Res And Dev Ltd PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATINES
EP2033631A3 (en) * 2002-09-03 2009-06-03 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
WO2005005481A2 (en) 2003-07-10 2005-01-20 Avitek Pharma Inc. Combination therapy for gastroenteric diseases caused by microorganisms
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
WO2005058861A1 (en) 2003-12-16 2005-06-30 Uk Chemipharm Co., Ltd. Process for preparing simvastatin.
WO2005115380A2 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20060111436A1 (en) 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2008151032A2 (en) 2007-05-31 2008-12-11 Washington University In St. Louis Arrays and methods comprising m. smithii gene products
WO2008151257A2 (en) * 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7970905B2 (en) 2008-07-03 2011-06-28 International Business Machines Corporation Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems
KR101751074B1 (ko) 2009-02-02 2017-06-26 크로모셀 코포레이션 신규한 세포주와 방법
UY32802A (es) 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
EP2943213A4 (en) * 2013-01-08 2016-08-17 Jerome Schentag ACTIVATION OF THE ENDOGENOUS HORMONE PATHWAY OF ILLEAL BRAKE FOR THE REGENERATION OF AN ORGAN AND ASSOCIATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
AU2014239164B2 (en) 2013-03-15 2018-12-06 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
RU2697851C2 (ru) 2014-08-13 2019-08-21 Седарс-Синаи Медикал Сентер Антиметаногенные композиции и их применение
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2017223177A1 (en) 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100023A2 (en) * 2002-05-20 2003-12-04 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
WO2006102350A1 (en) * 2005-03-23 2006-09-28 Washington University In St. Louis The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
CN101312716A (zh) * 2005-09-30 2008-11-26 Impax实验室公司 具有速释和/或控释特征的药物剂型
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Su1940：Methanobrevibacter Smithii is Highly Prominent in the Small Bowel of Rats";Emily Rooks et al;《gastroenterology》;20121231;S-541 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071673B2 (en) 2013-03-15 2024-08-27 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Also Published As

Publication number Publication date
RU2697851C2 (ru) 2019-08-21
US20200323781A1 (en) 2020-10-15
US20160045604A1 (en) 2016-02-18
RU2017106896A3 (enExample) 2019-03-19
US20190328885A1 (en) 2019-10-31
AU2015301596A1 (en) 2017-02-02
BR112017002761A2 (pt) 2017-12-19
MX2017001971A (es) 2017-09-15
AU2015301596B2 (en) 2020-04-16
KR102425303B1 (ko) 2022-07-25
CA2955666A1 (en) 2016-02-18
CN106687107A (zh) 2017-05-17
WO2016025762A1 (en) 2016-02-18
JP6667526B2 (ja) 2020-03-18
US10328151B2 (en) 2019-06-25
IL250568B (en) 2021-05-31
EP3179983A1 (en) 2017-06-21
US10668159B2 (en) 2020-06-02
US11344501B2 (en) 2022-05-31
US9956292B2 (en) 2018-05-01
US20180289816A1 (en) 2018-10-11
EP3179983A4 (en) 2018-01-10
KR20170041769A (ko) 2017-04-17
US20230036151A1 (en) 2023-02-02
IL250568A0 (en) 2017-03-30
JP2017528516A (ja) 2017-09-28
RU2017106896A (ru) 2018-09-13

Similar Documents

Publication Publication Date Title
US20230036151A1 (en) Anti-methanogenic compositions and uses thereof
US20230398093A1 (en) Anti-methanogenic lovastatin analogs or derivatives and uses thereof
KR20150046310A (ko) 완화제 조성물 및 변비 및 관련 위장관 질병 및 증상 치료를 위한 방법
US20200390742A1 (en) Clinically efficacious anti-methanogenic compositions and uses
JP7651620B2 (ja) 経口リファマイシンｓｖ組成物
Kuzuya Effect of drugs on nutritional status and drug–nutrition interactions in older patients
US20190277833A1 (en) Anti-methanogenic compositions
WO2017221886A1 (ja) 腸内環境改善剤
JP7763751B2 (ja) リファキシミン液体製剤
UA69824U (en) Composite enterosorbent
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome
HK40110949A (en) Oral rifamycin sv compositions
HK40110239A (en) Oral rifamycin sv compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201225